ANX is another company in the early stages of developing an HIV drug. I've read posts stating that potential suitors are more interested in Thiovir which is in pre-clinical then in Co-factor which is ANX's lead drug.
About Thiovir
Thiovir is a broad spectrum anti-viral and a non-nucleoside reverse transcriptase inhibitor (NNRTI) designed for oral delivery as a component of HAART. Thiovir is a prodrug for foscarnet that delivers both the active drug TPFA (thiophosphonoformate) and the active metabolite PFA (foscarnet) in an oral formulation. Thiovir is intended to deliver the benefits of the drug foscarnet, including broad spectrum antiviral activity, with the added benefit of improved bioavailability. ADVENTRX currently plans to file an investigational new drug application with the US Food and Drug Administration in the first half of 2006 for testing of Thiovir in patients with HIV/AIDS.
"Published data show that the avian influenza polymerase subsequence, PB1, is highly conserved. Since Thiovir's proposed mechanism of action is inhibition of the polymerase PB1 subunit, we began to investigate the possible use of Thiovir for avian flu," said Joan M. Robbins, Ph.D., ADVENTRX chief scientific officer and executive vice president. "Additional confirmatory tests for Thiovir in avian flu and other viruses are planned. A preclinical package for Thiovir with extensive pharmacology and toxicology studies is already in development for our HIV program and we believe this would help expedite the clinical development of Thiovir for other indications, such as in the treatment of avian flu."
AI
Market Data 
Markets 
